Axcellerate Pharma

What Axcellerate Pharma does

Axcellerate Pharma is a US-based, privately held contract research and contract development and manufacturing organization (CRO/CDMO) serving the biopharmaceutical industry. Founded around 2016 and led by Director Ashwin Mehta, the company operates multi-modality manufacturing facilities — including an ex-Pfizer facility and a Piscataway, NJ multi-faceted site — alongside an active North Carolina buildout. Its service portfolio spans contract research, cGMP API and intermediates manufacturing, aseptic filling (ISO Class 5–8 sterile environments), formulation development (liposomal, PEGylation, microsphere encapsulation), analytical method development and validation, and commercial generics manufacturing. Technical capabilities cover mammalian recombinant proteins/antibodies, microbial fermentation (5L–150L scale), small molecule synthesis, lyophilization cycle development, PEGylation, and oligonucleotide production.

The company addresses both small-to-mid biotech and large multinational biopharmaceutical clients, taking programs from preclinical discovery through process development, scale-up, and cGMP clinical supply under flexible engagement models. Revenue is generated primarily through Full-Time Equivalent (FTE) engagements, where clients pay for dedicated scientists and facility access, and Fee-for-Service (FFS) project-based contracts across research, API manufacturing, aseptic filling, formulation, and analytical work. Its commercial footprint also extends into generics manufacturing (lyophilization, control substances, hormones & steroids, cytotoxic/oncology) through an alliance with Generic Specialties.

Axcellerate pursues an M&A-led growth strategy, evidenced by the ex-Pfizer facility acquisition and the founder's stated specialization in asset and company acquisitions. The firm is founder-led, privately held, discloses no external investors or parent company, and provides no public revenue, headcount, or financial detail. Industry positioning leans on cGMP compliance credentials, a broad multi-modality offering unusual for a sub-250-person firm, and senior leadership with experience at Bristol-Myers Squibb, Immunomedics, and Enzon Pharmaceuticals.

Name

Axcellerate Pharma

Legal name

Axcellerate Pharma LLC

Website

https://axcelleratepharma.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

101–250 employees

Short description

Axcellerate Pharma is a US-based, privately held CRO/CDMO providing contract research, cGMP API manufacturing, aseptic filling, formulation development, and biologics capabilities — including mammalian cell culture, microbial fermentation, PEGylation, and oligonucleotide production — to small, mid, and large biopharmaceutical clients across multi-year FTE and FFS engagements.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development and Manufacturing (CDMO/CRO)

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule API & Intermediates CDMO (HLAGABAA), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Contract pharmaceutical manufacturing
• CGMP biologics manufacturing
• Sterile injectable fill-finish
• Active pharmaceutical ingredient manufacturing
• Biopharmaceutical contract research

Headquarters

HQ city

Piscataway

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Fee-for-Service (FFS) CDMO/CRO Contracts: Project-based pricing for contract research, API manufacturing, aseptic filling, formulation development, and analytical services — operates like a regular CRO/CDMO under a fee-for-service model.
2. Full-Time Equivalent (FTE) Engagements: FTE (Full Time Employee) model where clients pay for dedicated scientists and use of Axcellerate's facility for development and manufacturing segments — provides clients 'feet on the ground.'

Pricing tiers

Go-to-market motion1 record

Core offering

Axcellerate Pharma is a contract research, development, and manufacturing organization (CRO/CDMO) that provides cGMP clinical and commercial manufacturing services across small molecules, biologics, sterile injectables, and generics. Its offering combines contract research, API manufacturing, formulation development, cGMP aseptic filling, lyophilization, analytical services, and dedicated FTE/FFS engagement models for biotech and biopharmaceutical clients.

Product overview

Axcellerate Pharma deploys a unique combination of assets and operational capabilities to deliver integrated CRO/CDMO services for the biopharmaceutical industry. The platform is organized around two complementary pillars — service offerings and technical capabilities — that work together to take client programs from preliminary drug discovery through scale-up, cGMP manufacture, and clinical supply. The service layer includes Contract Research, API Manufacturing, cGMP Aseptic Filling, Formulation Development (including liposomal formulation, PEGylation, and microsphere encapsulation), Analytical Services, and flexible FTE (Full-Time Employee) / FFS (Fee-for-Service) engagement models. The capability layer covers Mammalian Biopharmaceuticals, Microbial Fermentation, Small Molecules, Lyophilization, PEGylation, and Oligonucleotides. These capabilities feed into three commercial manufacturing tracks: Generics (lyophilization, control substances, hormones & steroids, cytotoxic/oncology), Sterile Injectables (vials, syringes, cartridges, bags), and Biologics (mammalian cell culture, microbial fermentation, oligonucleotides, PEGylation). Together, the offerings accommodate drug product development activities and cGMP manufacture of early clinical supplies for both large and small molecules, including dedicated process areas for biologics development, chemical development, and sterile manufacturing with lyophilization.

Differentiator

Problem solved

Functional benefit

Products and services

• Contract Research

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Curia (formerly AMRI): Contract development and manufacturing organization providing API development, sterile injectable fill-finish, and biologics services. Comparable to Axcellerate across small molecule API, aseptic filling, and contract research offerings.
• PCI Pharma Services: Contract services provider for sterile injectables, lyophilization, and commercial packaging. Directly comparable to Axcellerate's sterile injectable manufacturing, lyophilization, and aseptic filling tracks, with a similar specialty-CDMO commercial positioning.
• Recipharm: European-headquartered CDMO offering small molecule API manufacturing, sterile injectables, and biologics services. Closely comparable to Axcellerate's small-molecule API, aseptic filling, and formulation development offerings, with a similar multi-modality CDMO model.
• Piramal Pharma Solutions: Contract development and manufacturing organization offering API development, sterile injectables, and complex formulations. Directly comparable to Axcellerate's API manufacturing, aseptic filling, and specialty generics (including hormones/steroids) capabilities.
• Alcami: U.S.-based mid-sized CDMO offering API manufacturing, analytical services, and sterile fill-finish. Closely comparable to Axcellerate in scale, modality mix, and the focus on cGMP API and aseptic services for biotech and specialty pharma clients.

Broad incumbents

• Lonza: Global leader in biologics CDMO services including mammalian cell culture, microbial fermentation, and aseptic manufacturing. Closely comparable to Axcellerate's mammalian biopharmaceuticals and microbial fermentation offerings, with far larger capacity and regulatory track record.
• Catalent: One of the largest global CDMOs offering biologics, sterile fill-finish, oral and specialty delivery formats. Directly comparable to Axcellerate across aseptic filling, formulation, and biologics capabilities, but at materially greater scale and with a much broader global footprint.
• Patheon (Thermo Fisher Scientific): Global CDMO within Thermo Fisher's pharma services segment, providing API, biologics, and sterile manufacturing at scale. Overlaps with Axcellerate's API manufacturing, biologics, and aseptic filling capabilities, but operates as part of a much larger diversified life sciences platform.
• WuXi Biologics: End-to-end biologics CDMO offering discovery, development, and manufacturing services including mammalian and microbial platforms. Comparable in modality mix to Axcellerate's biologics capability layer, though global in scale and with significantly deeper financial resources.
• Samsung Biologics: Large-scale biologics CDMO with mammalian cell culture and aseptic fill-finish capacity. Comparable to Axcellerate's biologics track but operating at a fundamentally different scale and exclusively focused on biologics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/AxcellratPharma
• Facebookfacebook.com/axcellerate.pharma

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Axcellerate Pharma